FRX.TO - Fennec Pharmaceuticals Inc.
| Previous Close | 5.93 |
| Open | 6.05 |
| Bid | 5.84 x 0 |
| Ask | 6.07 x 0 |
| Day's Range | 5.93 - 6.05 |
| 52 Week Range | 4.35 - 10.70 |
| Volume | 200 |
| Avg. Volume | 487 |
| Market Cap | 117.982M |
| Beta (3Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.67 |
| Earnings Date | Mar. 29, 2018 - Apr. 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Fennec Pharmaceuticals Inc.
Announced that CEO Rosty Raykov will present at the Cantor Fitzgerald Global Healthcare Conference in ...
- GlobeNewswire
Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2019 -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM.
- GlobeNewswire
Fennec Appoints Jodi A. Cook, PhD to Its Board of Directors
TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has appointed Jodi A. Cook, PhD to its board of directors. Dr. Cook currently serves as Head of Gene Therapy Strategy at PTC Therapeutics, Inc., a global biopharmaceutical company focused on the development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.
- GlobeNewswire
Fennec Appoints Shubh Goel as Chief Commercial Officer
TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has appointed Shubh Goel as chief commercial officer. In this newly created position, Ms. Goel will build and oversee Fennec’s commercial strategy and organization, including the launch and commercialization of PEDMARK™, if approved. “I am thrilled to join Fennec at such a transformative moment, as we prepare for the potential commercial launch of PEDMARK,” said Ms. Goel.
- GlobeNewswire
Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09,.
- GlobeNewswire
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 19, 2019 -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management.
- GlobeNewswire
Fennec Provides Business Update and Announces First Quarter 2019 Financial Results
Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK,.
- GlobeNewswire
Fennec Provides Business Update and Announces Fiscal Year 2018 Financial Results
Initiated rolling New Drug Application to U.S. FDA for PEDMARKTMSecured $12. 5 million debt financing to support a potential commercial launch Strong financial position with.
- GlobeNewswire
Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank
The U.S. operating subsidiary of Fennec Pharmaceuticals Inc. entered into a Loan and Security Agreement with Bridge Bank, securing a $12.5 million debt facility with a maturity date of October 1, 2023, which will be funded upon New Drug Application (NDA) approval of PEDMARKTM in the U.S. The Company intends to use the proceeds from the loan to provide working capital for commercialization activities for PEDMARKTM upon NDA approval. “We welcome the commitment of Bridge Bank to Fennec as this debt facility provides us with the option to access minimally dilutive capital at an attractive cost upon NDA approval.
- ACCESSWIRE
Today's Research Reports on Hemostemix, Fennec Pharmaceuticals, Sernova and Covalon Technologies
NEW YORK, NY / ACCESSWIRE / January 10, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...
- GlobeNewswire
Fennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK™
PEDMARKTM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to
- ACCESSWIRE
Today's Research Reports on Fennec Pharmaceuticals, Baylin Technologies, Canopy Growth and CardioComm Solutions
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...
- GlobeNewswire
Fennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM.
- GlobeNewswire
Fennec Provides Business Update and Announces Third Quarter 2018 Financial Results
Positive Opinion on the Pediatric Investigation Plan from EMA for PEDMARKTMTargeting US approval of PEDMARKTM in the second half of 2019Strong financial position with $24.5.
- ACCESSWIRE
Today's Research Reports on Fennec Pharmaceuticals, Baylin Technologies, CRH Medical and Cotinga Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / October 30, 2018 / MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...